K
Kai M. Beeh
Researcher at Imperial College London
Publications - 14
Citations - 1461
Kai M. Beeh is an academic researcher from Imperial College London. The author has contributed to research in topics: COPD & Tiotropium bromide. The author has an hindex of 11, co-authored 14 publications receiving 1355 citations.
Papers
More filters
Journal ArticleDOI
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Claus Vogelmeier,Bettina Hederer,Thomas Glaab,Hendrik Schmidt,Maureen P.M.H. Rutten-van Mölken,Kai M. Beeh,Klaus F. Rabe,Leonardo M. Fabbri +7 more
TL;DR: Results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations.
Journal ArticleDOI
Neutrophil Chemotactic Activity of Sputum From Patients With COPD: Role of Interleukin 8 and Leukotriene B4
TL;DR: In this article, the contribution of interleukin (IL)-8 and leukotriene B 4 (LTB 4 ) to neutrophil chemotaxis evoked by sputum obtained from patients with established COPD was assessed.
Journal ArticleDOI
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
TL;DR: Improvements in exercise endurance increased over time, suggesting that mechanisms beyond improved lung function may be involved in enhanced exercise tolerance.
Journal ArticleDOI
The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
Kai M. Beeh,Eric Derom,Jose Echave-Sustaeta,Lars Grönke,Alan Hamilton,Dongmei Zhai,Leif Bjermer +6 more
TL;DR: Once-daily tiotropium + olodaterol in participants with moderate-to-severe COPD provided superior lung function improvements to twice-daily salmeterol + fluticasone propionate, which can be considered to optimize lung function in individuals requiring maintenance treatment for COPD.
Journal ArticleDOI
Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma
TL;DR: Once-daily indacaterol at doses of 200 and 400 µg provided sustained 24-h bronchodilation, with a rapid onset and a good tolerability and safety profile.